Searched for
JUBILANT ORGANOSYS
- Jubilant wants remaining stake of Cadista HoldingsJubilant Life Sciences (formerly Jubilant Organosys) has offered to buy 17.6% stake in US-based Cadista Holdings Inc for Rs 28 crore to mak...
- Jubilant Organosys up on $51 million CRAMS contractJubilant Organosys has signed a long term contract in CRAMS business with a leading US Life Sciences company.
- Jubilant Organosys Q1 net halves to Rs 63 crJubilant Organosys’ consolidated net profit for the quarter ended June halved to Rs 63 crore from the same period previous year, due to for...
- 'Buy Jubilant Organosys at Rs 370, target Rs 395'In a chat with ET Now, Sandeep Wagle, Founder & MD, APTART Technical Advisory Services, talks about the outlook of Jubilant Organosys.
- Buy Jubilant Organosys; target 455: Emkay Global Financial ServicesSharmila Joshi, Co-Head PCG Sales, Emkay Global Financial Services in an interview with ET Now talks about Jubilant Organosys.
- 'Target Rs 455 Jubilant Organosys'In a chat with ET Now, Sharmila Joshi, Co-head PCG Sales, Emkay Global Financial Services, talks about the outlook of Jubilant Organosys.
- Recommend a buy on Jubilant Organosys in 364-362 range: Sandeep Wagle, APTART Technical Advisory ServicesSandeep Wagle, Founder & MD, APTART Technical Advisory Services, in a chat with ET Now talks about Jubilant Organosys.
- Jubilant Organosys net up at Rs 137 crJubilant Organosys rode revenues from three manufacturing contracts and improved sales of key inputs to post a consolidated net profit of R...
- Jubilant Organosys Q4 net jumps 11-folds to Rs 137 crJubilant Organosys today reported an 11-fold jump in its consolidated net profit at Rs 137.16 crore for the fourth quarter.
- Jubilant Organosys to raise Rs 500 cr via share salePharmaceutical firm Jubilant Organosys on Friday said it will raise Rs 500 crore by placing shares with qualified institutional buyers
- Jubilant Organosys should find a strong support at 300: Devang VisariaDevang Visaria, Chief Strategist, devangvisaria.com in a chat with ET Now gives his take on Jubilant Organosys.
- Jubilant to hive off non-core businessPharmaceutical company Jubilant Organosys is demerging its non-core business - agri and performance polymer - into a separate subsidiary to...
- Jubilant extends collaboration with Eli LillyPharma company Jubilant Organosys has extended its four-year-old drug research collaboration with Eli Lilly for another five years.
- Jubilant recalls blood pressure drug in UKJubilant Organosys has recalled blood pressure drug amlodipine 5mg and 10mg in UK after its Indian contract manufacturer failed to meet the...
- Jubilant Organosys ties up with US-based Endo PharmaceuticalsThe focus of the tie-up is to develop pre-clinical candidates for joint clinical development, a Jubilant Organosys release said.
- Jubilant Organosys in drug discovery partnership with BioLeapJubilant Organosys has entered into a drug discovery partnership with US-based BioLeap, LLC.
- Eli Lilly, Jubilant Organosys form R&D joint ventureEli Lilly and Jubilant Organosys have formed a 50:50 R&D joint venture (JV) to develop molecules across several thereupatic areas.
- Jubilant Organosys slumps nearly 6% as net profit plungesJubilant Organosys fell as much as 5.7 per cent after the chemicals and drugs maker posted a 91 per cent fall in consolidated net profit fr...
- Jubilant Organosys bags new contracts worth $92 mn for 2008Jubilant Organosys Ltd has announced new contracts worth $92 million for its proprietary products and exclusive synthesis segment for 2008.
- Jubilant ties up with ForestJubilant Organosys has entered into an agreement with US-based Forest Laboratories for discovery of drug candidates for a metabolic disorde...
Load More- 'Buy Jubilant Organosys at Rs 370, target Rs 395'
